We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectivelyFull Year 2025 ...

More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

while being able to culture the B-cells with standard procedures. This allows for the isolation of therapeutic antibodies from rare B-cell clones, and accelerated functional screening and ...

HLA testing has been a staple in transplantation since the recognition that antibodies, directed against lymphocytes, were associated with allograft failure. This seminal finding led to the ...

These findings indicate that the utilization of hesperetin and the selectively overexpression of ADGRA3 in adipose tissue could serve as promising therapeutic strategies ... were repeated 2-3 ...

Antibody fragment therapies are a type of biologic. They are typically fragments of monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced ...

Treatment typically involves powerful chemotherapy, bone marrow/stem cell transplant, targeted therapy (tyrosine kinase inhibitors), monoclonal antibodies ... Stem cell transplants are major ...

Doctors at AIIMS, Delhi are developing a low-cost, antibody-based adaptive cellular therapy targeting multiple myeloma, a type of blood cancer. This innovation aims to make advanced treatments like ...